Vijay kumar Nagabandi, Swapna Sambaraj
The main objective of the current review is to cover the overview of silica lipid hybrid microparticles. Lipid-based delivery systems recognized as a potential strategy for improving the oral absorption. Clinical applications of many lipid-based formulations are limited by the lack of clear guidelines of incomplete understanding of absorption mechanism and in vitro, in vivo formulation performance. Withstanding these problems, the availability of 2-4% oral lipid based products in the pharmaceutical market worldwide has supported in addressing low bioavailability of poorly soluble drugs. A novel silica-lipid hybrid microparticulate system is used for enhancing the oral absorption of low solubility and low permeability of (BCS Class IV) drugs. It describes the systematic in vitro characterization of dissolution and lipolysis properties. Silica-lipid hybrid microparticles include the drug solubilising effect of dispersed lipids and stabilizing effect of hydrophilic silica particles to increase drug solubilisation, which leads to enhanced oral bioavailability. Hence, silica lipid microparticles can be used to enhance the bioavailability of BCS class IV drugs effectively.
